Literature DB >> 21801679

Prostate cancer screening: Canadian guidelines 2011.

Jonathan I Izawa1, Laurence Klotz, D Robert Siemens, Wassim Kassouf, Alan So, John Jordan, Michael Chetner, Alla E Iansavichene.   

Abstract

Entities:  

Year:  2011        PMID： 21801679      PMCID： PMC3147035          DOI： 10.5489/cuaj.11134

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  65 in total

1.  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Authors: 
Journal:  Ann Intern Med       Date:  2008-08-05       Impact factor: 25.391

2.  Transrectal prostate ultrasonography: variability of interpretation.

Authors:  M I Resnick; J A Smith; P T Scardino; M J Egger; A Hernandez; S C Rose
Journal:  J Urol       Date:  1997-09       Impact factor: 7.450

3.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.

Authors:  Anthony V D'Amico; Ming-Hui Chen; Kimberly A Roehl; William J Catalona
Journal:  N Engl J Med       Date:  2004-07-08       Impact factor: 91.245

4.  Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.

Authors:  Anna Bill-Axelson; Lars Holmberg; Frej Filén; Mirja Ruutu; Hans Garmo; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Juni Palmgren; Hans-Olov Adami; Jan-Erik Johansson
Journal:  J Natl Cancer Inst       Date:  2008-08-11       Impact factor: 13.506

5.  Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations.

Authors:  James A Eastham; Elyn Riedel; Peter T Scardino; Moshe Shike; Martin Fleisher; Arthur Schatzkin; Elaine Lanza; Lianne Latkany; Colin B Begg
Journal:  JAMA       Date:  2003-05-28       Impact factor: 56.272

6.  Prognostic significance of visible lesions on transrectal ultrasound in impalpable prostate cancers: implications for staging.

Authors:  Herbert Augustin; Markus Graefen; Jüri Palisaar; Jakob Blonski; Andreas Erbersdobler; Fedor Daghofer; Hartwig Huland; Peter G Hammerer
Journal:  J Clin Oncol       Date:  2003-08-01       Impact factor: 44.544

7.  Pathological characteristics of prostate cancer detected through prostate specific antigen based screening.

Authors:  Stacy Loeb; Chris M Gonzalez; Kimberly A Roehl; Misop Han; Jo Ann V Antenor; Ronald L Yap; William J Catalona
Journal:  J Urol       Date:  2006-03       Impact factor: 7.450

8.  Prostate cancer screening: role of the digital rectal examination and prostate-specific antigen.

Authors:  J P Richie; L R Kavoussi; G T Ho; M A Vickers; M A O'Donnell; D St Laurent; A Chen; D S Goldstein; K R Loughlin
Journal:  Ann Surg Oncol       Date:  1994-03       Impact factor: 5.344

9.  Validation of the contemporary epstein criteria for insignificant prostate cancer in European men.

Authors:  Claudio Jeldres; Nazareno Suardi; Jochen Walz; Georg C Hutterer; Sascha Ahyai; Jean-Baptiste Lattouf; Alexander Haese; Markus Graefen; Andreas Erbersdobler; Hans Heinzer; Hartwig Huland; Pierre I Karakiewicz
Journal:  Eur Urol       Date:  2007-12-07       Impact factor: 20.096

10.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245
View more
  29 in total

1.  Prostate cancer screening: Attitudes and practices of family physicians in Ontario.

Authors:  Christopher B Allard; Shawn Dason; Janis Lusis; Anil Kapoor
Journal:  Can Urol Assoc J       Date:  2012-06       Impact factor: 1.862

2.  PSA testing still essential.

Authors:  Tony Finelli
Journal:  Can Urol Assoc J       Date:  2011-12       Impact factor: 1.862

3.  La mesure de l'APS demeure essentielle.

Authors:  François Bénard
Journal:  Can Urol Assoc J       Date:  2011-12       Impact factor: 1.862

4.  The confusion surrounding prostate cancer screening faced by family physicians.

Authors:  Nathan A Hoag; Alan I So
Journal:  Can Urol Assoc J       Date:  2012-06       Impact factor: 1.862

5.  Prostate-specific antigen screening can be beneficial to younger and at-risk men.

Authors:  Monique J Roobol; Chris H Bangma; Stacy Loeb
Journal:  CMAJ       Date:  2012-05-07       Impact factor: 8.262

6.  Variations in prostate biopsy practice: A quantitative questionnaire-based study.

Authors:  Matthew O Lipinski; D Robert Siemens; Patti A Groome
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

7.  The decline and fall of RCTs.

Authors:  Laurence H Klotz
Journal:  Can Urol Assoc J       Date:  2011-08       Impact factor: 1.862

8.  Recommendations on screening for prostate cancer with the prostate-specific antigen test.

Authors:  Neil Bell; Sarah Connor Gorber; Amanda Shane; Michel Joffres; Harminder Singh; James Dickinson; Elizabeth Shaw; Lesley Dunfield; Marcello Tonelli
Journal:  CMAJ       Date:  2014-10-27       Impact factor: 8.262

9.  Challenging the 10-year rule: The accuracy of patient life expectancy predictions by physicians in relation to prostate cancer management.

Authors:  Kevin M Y B Leung; Wilma M Hopman; Jun Kawakami
Journal:  Can Urol Assoc J       Date:  2012-10       Impact factor: 1.862

10.  Active treatment in low-risk prostate cancer: a population-based study.

Authors:  S Roy; M E Hyndman; B Danielson; A Fairey; R Lee-Ying; W Y Cheung; A R Afzal; Y Xu; T Abedin; H C Quon
Journal:  Curr Oncol       Date:  2019-08-01       Impact factor: 3.677
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.